LiveLoadingtotal visitors

Open source
Global perspectives

A short history of diabetes research

From early clinical descriptions to insulin, molecular understanding, monitoring, immune modulation, and cell replacement.

2 min readEasy read4 sourcesChecked 30 Sept 2026Established

By The Diabetes Guide editorial project · Updated 30 Sept 2026

On this page
In simple words

Before insulin, severe diabetes could be fatal quite quickly. Insulin was made ready for use in 1921–1922, and tools have improved ever since.

  1. Step 1: 1921–1922

    The Toronto team’s work led to the first treatment of a patient with insulin in 1922.

    For example: A lifeboat arriving after a long wait.

  2. Step 2: Better tools

    Purified insulin, meters, HbA1c, pumps, CGM and new medicines built step by step.

    For example: From candle to lightbulb to smart lamp.

  3. Step 3: Still unfinished

    Devices manage sugar; cell therapy needs immune care. A cure is not guaranteed by history.

    For example: A good start does not make the finish line closer than it is.

Remember: Each milestone solved one problem, not every problem.

The full story

Want more? Below is the detailed version with the real science words. It is fine to skip it.

The turning point

Before insulin treatment, severe insulin-deficient diabetes was generally fatal within a short period. The Toronto work in 1921 and treatment of Leonard Thompson in 1922 transformed that outlook. Banting, Best, Macleod and Collip contributed through experimental work, leadership and purification; discovery was a collective scientific process. 1

  1. Ancient descriptions

    Physicians describe excessive urination and wasting, without modern disease classification.

  2. 19th century

    Experimental research increasingly connects the pancreas to glucose regulation.

  3. 1921

    The Toronto insulin experiments establish a transformative treatment direction.

  4. 1922

    Human insulin treatment becomes a clinical reality.

  5. Later 20th century

    Purified and recombinant insulin, glucose meters, HbA1c measurement and pumps reshape management.

  6. 21st century

    CGM and automated delivery connect sensing to treatment; incretin therapies broaden Type 2 options.

  7. 2025–2026

    Cell-replacement evidence and expanded immune-modulation indications address disease mechanisms.

Progress does not erase the remaining work

Devices can improve regulation while autoimmunity persists. Cell therapy can restore secretion while immune suppression remains necessary. Historical milestones should be read as specific capabilities gained, not a narrative that makes a universal cure inevitable. 234

Trace the evidence

Sources and further reading

1.The discovery of insulin (opens in a new tab)

Nobel Prize educational archive · 2026 · Reference

Established
Who was studied, limits and source check

Limitations: Historical educational account accessed in 2026; not a clinical evidence source.

Source checked 2026-09-30. See the original publication for full methods.

2.Diabetes Technology: Standards of Care 2026 (opens in a new tab)

American Diabetes Association · 2026 · Guideline

Strong Evidence
Who was studied, limits and source check

Limitations: Access, training, device labeling, and safe-use capacity affect applicability.

Source checked 2026-09-30. See the original publication for full methods.

3.FDA accelerated approval: teplizumab in selected recently diagnosed pediatric Stage 3 T1D (opens in a new tab)

US Food and Drug Administration · 2026 · Regulatory

Strong Evidence
Who was studied, limits and source check

Population: Children aged 8–17 recently diagnosed with Stage 3 T1D

Sample: PROTECT: 328 participants

Limitations: June 12 accelerated approval based on C-peptide preservation, a surrogate. Confirmatory clinical benefit and label conditions matter.

Source checked 2026-09-30. See the original publication for full methods.

4.Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes (opens in a new tab)

Reichman et al.; New England Journal of Medicine · 2025 · Early human study

Preliminary
Who was studied, limits and source check

Population: Selected adults with T1D, severe hypoglycemia and impaired awareness

Sample: 14 with ≥12-month follow-up; 12 at full dose

Limitations: Small, uncontrolled interim analysis; required immunosuppression; serious adverse events and deaths occurred. Not a routine cure.

Source checked 2026-09-30. See the original publication for full methods.

Source checking is an editorial literature check, not independent medical review. This page is for learning. It cannot diagnose you or make a treatment plan. Evidence labels describe the cited claims, not the whole topic.

What does “Established” mean?

Doctors and scientists agree. This is well known. Like “the sun rises in the east”.

The body

The one-page mental model

Diabetes means there is too much sugar in the blood for too long, because the body does not have enough insulin or cannot use it well.

4 minEasy read

Type 1

Type 1 diabetes: the complete journey

Type 1 diabetes is usually an autoimmune condition. The body’s defence system harms the beta cells, so less and less insulin is made.

4 minEasy read